Drug Packaging and Labelling Under CDSCO: A Practical Guide for Manufacturers and Importers

CDSCO enforces labelling and packaging rules through the Drugs and Cosmetics Act 1940 and the Drugs and Cosmetics Rules 1945. Every drug that needs a CDSCO Certificate goes through a label review. Every imported formulation that requires DCGI Approval gets its artwork checked. Errors at this stage don't just delay approvals they send applications back to square one.

The Rules Behind the Requirements

Rules 96 and 97 of the Drugs and Cosmetics Rules, 1945 are what most regulatory consultants refer to when a client asks about label compliance. Rule 96 covers the innermost container. Rule 97 deals with the outer carton and the package insert. Together, they define what must appear, in what form, and in what proportion.

For anyone pursuing CDSCO Medical Device Registration or CDSCO Registration for Medical Devices, the Medical Devices Rules, 2017 apply instead with their own set of labelling demands. DCGI Approval, in both cases, is the final sign-off. No product moves to market without it.

One thing that catches importers off guard: changing an approved label after receiving the CDSCO Certificate is not a minor administrative step. It requires fresh DCGI Approval. Even a font change. Even shifting the batch number field. The artwork locked into the dossier is the artwork that goes on the shelf.

Read MoreWhat is CDSCO Medical Device Import Certificate?

What Has to Be on the Label

There is no discretion here. These are fixed requirements under CDSCO norms:

• The drug name, both brand and INN, must appear together. The INN, or International Non-proprietary Name, cannot be printed smaller than the brand name. This gets flagged regularly during CDSCO registration review. It sounds simple. It still trips people up.

• Active ingredients must be listed with their exact quantities per unit dose. Salt forms matter too. A tablet containing atorvastatin calcium equivalent to 10 mg atorvastatin needs to say exactly that the equivalent phrasing is not optional.

• Manufacturer details go beyond a company name. The full address, manufacturing licence number, and for imported drugs, the country of origin and Indian importer's information all of it must be present. Partial information is treated the same as missing information.

• Batch number, manufacturing date, and expiry date are traceable markers. If a product is recalled, these are what regulators use to identify affected stock. Expiry must be in month and year format. "Best before" language doesn't work here.

• Storage conditions on the label must match what the stability study says. Not approximate it match it. If the dossier states "Store between 2°C and 8°C, protected from light," the label carries exactly that. Cold-chain products face additional scrutiny during CDSCO certification review for this reason.

• Schedule classification is the one element that catches first-time applicants most often, especially those going through CDSCO registration in Noida and nearby manufacturing zones for the first time. Schedule H, H1, and X drugs each carry distinct mandatory markings. Prescription-only drugs carry the red strip and "Rx." Leaving this off is not a minor oversight it's a scheduling violation.

  Have Questions? Let’s Talk. We’re Just One Click Away.

  Submit

• MRP must appear inclusive of all taxes, as required under the Legal Metrology (Packaged Commodities) Rules, 2011. This applies even when the product is moving through institutional channels.

Packaging Material Is Important Too

The container is not separate from the compliance requirement. Primary packaging whatever makes direct contact with the drug must meet Indian Pharmacopoeia standards or an accepted international equivalent. Injectables go into Type II or Type III glass. Blister packs need approved foil and film specs. These material choices are documented in the dossier submitted for CDSCO Registration and cannot be swapped out after approval without going back to DCGI.

For CDSCO Registered Medical Device products, the packaging has to maintain the device's sterility or functional integrity through the entire stated shelf life. That means validated packaging processes not just using a vendor that seems reliable. The outer carton must be tamper-evident. It cannot carry claims that weren't approved as part of the original application.

Read MoreWhat is CDSCO Registration?

How Agile Regulatory Works With You

Agile Regulatory assists manufacturers, importers and distributors with CDSCO Registration, CDSCO Certification, Medical Device Registration and DCGI Approval across PAN India.

The team reviews label artwork prior to dossier submission, flags issues which would otherwise come back as queries and coordinates directly with CDSCO offices throughout the process. That approach has built a track record with clients in the pharmaceutical, medical device and cosmetics sectors for more than 15 years.

FAQs

1. Which rules specifically govern drug labeling in India? 

Rules 96 and 97 of the Drugs and Cosmetics Rules, 1945. Rule 96 covers the innermost container, and Rule 97 covers the outer packaging and insert. CDSCO enforces both as part of the registration review.

2. Can a label be changed after receiving the CDSCO certificate?

Not without prior DCGI approval. Any change, including font, layout, or field placement, requires fresh approval before the updated label enters commercial use.

3. Does CDSCO Registration for Medical Devices include packaging requirements? 

Yes. Material specifications, sterility maintenance, and IFU documentation are all part of the technical dossier reviewed during CDSCO medical device registration.

4. What happens when a CDSCO Registered Medical Device has a labelling violation?

Depending on the severity, the consequences range from a show-cause notice to product recall or cancellation of the CDSCO Certificate. State Drug Controllers have independent powers to act on labelling non-compliance.

Post Views: 855

• Facebook
• Whatsapp
• Linkedin
• Pinterest
• X
• Facebook

ABOUT THE AUTHOR

Nishi Chawla

Content Writer & Compliance Specialist

Nishi is an expert content writer having an expertise in writing Business Legal Compliances, Certifications, and Registrations. She is an expert in BIS, EPR, Medical Devices, Cosmetics, Drugs, and Import Export having completed her bachelor’s of commerce from one of the most prestigious universities in India, University of Delhi. She has been writing content since 2019 for multiple firms including Agile Regulatory, Creation Infoways, and Devlofox Technologies.

View Profile